MX2020005213A - Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. - Google Patents

Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Info

Publication number
MX2020005213A
MX2020005213A MX2020005213A MX2020005213A MX2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A MX 2020005213 A MX2020005213 A MX 2020005213A
Authority
MX
Mexico
Prior art keywords
inhibitors
compositions
methods
same
present
Prior art date
Application number
MX2020005213A
Other languages
English (en)
Inventor
Russell C Petter
Deqiang Niu
Matthew David Alexander
Joseph John Mcdonald
Yike Ni
Juswinder Singh
Claudio Chuaqui
John Malona
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MX2020005213A publication Critical patent/MX2020005213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

La presente invención proporciona compuestos, composiciones de los mismos y métodos para utilizarlos.
MX2020005213A 2014-09-17 2017-03-14 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. MX2020005213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31

Publications (1)

Publication Number Publication Date
MX2020005213A true MX2020005213A (es) 2020-08-20

Family

ID=55454109

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003359A MX2017003359A (es) 2014-09-17 2015-09-16 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2020005213A MX2020005213A (es) 2014-09-17 2017-03-14 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017003359A MX2017003359A (es) 2014-09-17 2015-09-16 Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.

Country Status (30)

Country Link
US (5) US9458175B2 (es)
EP (2) EP3193611B1 (es)
JP (3) JP6556225B2 (es)
KR (1) KR102457848B1 (es)
CN (1) CN106998692B (es)
AU (1) AU2015317741B2 (es)
BR (1) BR112017005266B1 (es)
CA (1) CA2961607C (es)
CL (1) CL2017000576A1 (es)
CO (1) CO2017003279A2 (es)
CY (1) CY1124215T1 (es)
DK (1) DK3193611T3 (es)
EA (1) EA037299B1 (es)
EC (1) ECSP17023281A (es)
ES (1) ES2874561T3 (es)
HR (1) HRP20210529T1 (es)
HU (1) HUE054347T2 (es)
IL (1) IL251051B (es)
LT (1) LT3193611T (es)
MA (1) MA40534B1 (es)
MX (2) MX2017003359A (es)
NZ (1) NZ730603A (es)
PL (1) PL3193611T3 (es)
PT (1) PT3193611T (es)
RS (1) RS62017B1 (es)
SA (1) SA517381115B1 (es)
SG (2) SG11201701861RA (es)
SI (1) SI3193611T1 (es)
TW (1) TWI744217B (es)
WO (1) WO2016044463A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
ES2874561T3 (es) 2014-09-17 2021-11-05 Celgene Car Llc Inhibidores de MK2 y usos de los mismos
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
AU2018236290B2 (en) * 2017-03-16 2022-06-02 Bristol-Myers Squibb Company MK2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
EP3595658A4 (en) * 2017-03-16 2020-11-25 Celgene CAR LLC FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
AU2021218740A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Mono and combination therapies with ULK1/2 inhibitors
EP4114411A4 (en) * 2020-03-02 2024-04-24 Washington University St Louis COMPOSITIONS AND METHODS FOR THE TREATMENT OF PANCREATIC CANCER
JP2023536427A (ja) * 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1572693A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Ｍｋ２阻害剤として有用なヘテロ環式化合物
US8907095B2 (en) 2007-10-22 2014-12-09 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (ko) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. 헤테로아릴 화합물 및 이의 용도
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) * 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN107057719A (zh) 2012-02-22 2017-08-18 默克专利股份有限公司 液晶介质
JPWO2013146963A1 (ja) * 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
US20150269216A1 (en) * 2012-09-24 2015-09-24 Claremont Speede Mobile sender controlled data access and data deletion method and system
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
KR20150133172A (ko) * 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
ES2874561T3 (es) 2014-09-17 2021-11-05 Celgene Car Llc Inhibidores de MK2 y usos de los mismos
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
EP3595658A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC FORMS AND COMPOSITIONS OF A MK2 INHIBITOR
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
AU2018236290B2 (en) 2017-03-16 2022-06-02 Bristol-Myers Squibb Company MK2 inhibitors, synthesis thereof, and intermediates thereto
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4.5] THIENO [3,2-F] QUINOLINE-8-ON COMPOUNDS AND USES THEREOF
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法

Also Published As

Publication number Publication date
JP2017529367A (ja) 2017-10-05
TW201617351A (zh) 2016-05-16
EP3193611B1 (en) 2021-03-24
JP2022078315A (ja) 2022-05-24
WO2016044463A3 (en) 2016-09-01
US10253040B1 (en) 2019-04-09
CN106998692B (zh) 2020-09-08
IL251051B (en) 2019-11-28
CA2961607C (en) 2023-03-28
SA517381115B1 (ar) 2021-03-09
MA40534B1 (fr) 2021-04-30
US20160075720A1 (en) 2016-03-17
BR112017005266B1 (pt) 2022-11-01
ECSP17023281A (es) 2017-06-30
CL2017000576A1 (es) 2017-12-01
CA2961607A1 (en) 2016-03-24
CN106998692A (zh) 2017-08-01
JP7375072B2 (ja) 2023-11-07
MX2017003359A (es) 2017-11-22
JP6556225B2 (ja) 2019-08-07
LT3193611T (lt) 2021-08-25
PL3193611T3 (pl) 2021-10-04
CO2017003279A2 (es) 2017-09-29
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
EP3193611A2 (en) 2017-07-26
WO2016044463A2 (en) 2016-03-24
SI3193611T1 (sl) 2021-08-31
PT3193611T (pt) 2021-05-28
NZ730603A (en) 2024-02-23
US9790235B2 (en) 2017-10-17
US20210053984A1 (en) 2021-02-25
BR112017005266A2 (pt) 2017-12-12
EA201790380A1 (ru) 2017-08-31
KR102457848B1 (ko) 2022-10-25
US20170114073A1 (en) 2017-04-27
RS62017B1 (sr) 2021-07-30
SG10201902326XA (en) 2019-04-29
AU2015317741A1 (en) 2017-04-20
US20190375762A1 (en) 2019-12-12
IL251051A0 (en) 2017-04-30
US11584757B2 (en) 2023-02-21
EA037299B1 (ru) 2021-03-05
US10577380B2 (en) 2020-03-03
US9458175B2 (en) 2016-10-04
HUE054347T2 (hu) 2021-08-30
JP2019194236A (ja) 2019-11-07
SG11201701861RA (en) 2017-04-27
TWI744217B (zh) 2021-11-01
DK3193611T3 (da) 2021-05-10
AU2015317741B2 (en) 2020-01-16
EP3193611A4 (en) 2018-02-28
MA40534A (fr) 2016-03-24
KR20170063734A (ko) 2017-06-08
CY1124215T1 (el) 2022-05-27
EP3912981A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2018003491A (es) Represores de htt y usos de estos.
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018001890A (es) Compuestos biciclicos como inhibidores de autotaxina (atx).
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
PH12016502213A1 (en) Novel compositions, uses and methods for making them
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
PH12017501864A1 (en) Compositions and methods for treating autism
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
TW201613892A (en) Forms and compositions of an ERK inhibitor